We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,050 | 22:29:19 |
From May 2019 to May 2024
By Dana Cimilluca, Cara Lombardo and Jonathan D. Rockoff
Novartis AG is nearing a deal to buy cholesterol-drug maker the Medicines Co. for nearly $7 billion, in an expensive bid to expand its reach in the lucrative market for heart treatments.
The Swiss pharmaceutical giant has agreed to pay $85 a share in a deal that could be announced this weekend, people familiar with the matter said.
The acquisition would help Novartis, which has a market value of more than $200 billion, bulk up in a corner of the health-care market it is already targeting with drugs including its heart-failure treatment Entresto.
(More to come)
(END) Dow Jones Newswires
November 23, 2019 14:11 ET (19:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
